Amalgamated Bank Purchases 258 Shares of Cambrex Corporation (CBM)

Amalgamated Bank lifted its position in shares of Cambrex Corporation (NYSE:CBM) by 6.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 4,473 shares of the biotechnology company’s stock after acquiring an additional 258 shares during the period. Amalgamated Bank’s holdings in Cambrex Corporation were worth $267,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in CBM. First Trust Advisors LP bought a new position in shares of Cambrex Corporation during the first quarter worth about $1,154,000. UBS Asset Management Americas Inc. grew its position in shares of Cambrex Corporation by 56.7% during the first quarter. UBS Asset Management Americas Inc. now owns 19,438 shares of the biotechnology company’s stock worth $1,070,000 after acquiring an additional 7,035 shares during the last quarter. Karp Capital Management Corp bought a new position in shares of Cambrex Corporation during the first quarter worth about $525,000. Parametric Portfolio Associates LLC grew its position in shares of Cambrex Corporation by 6.7% during the first quarter. Parametric Portfolio Associates LLC now owns 88,976 shares of the biotechnology company’s stock worth $4,898,000 after acquiring an additional 5,624 shares during the last quarter. Finally, Ameritas Investment Partners Inc. bought a new position in shares of Cambrex Corporation during the first quarter worth about $151,000.

Cambrex Corporation (NYSE:CBM) last released its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The business had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. During the same period in the previous year, the business posted $0.68 earnings per share. The firm’s revenue for the quarter was up 13.4% compared to the same quarter last year.

In related news, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $51.53, for a total value of $618,360.00. Following the completion of the transaction, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at $4,912,251.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven M. Klosk sold 4,000 shares of Cambrex Corporation stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the completion of the transaction, the chief executive officer now directly owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The disclosure for this sale can be found here. Insiders sold 28,000 shares of company stock valued at $1,574,880 over the last ninety days. 2.48% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Amalgamated Bank Purchases 258 Shares of Cambrex Corporation (CBM)” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/2956806/amalgamated-bank-purchases-258-shares-of-cambrex-corporation-cbm.html.

Several equities analysts have recently commented on the stock. BidaskClub lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. ValuEngine upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, August 22nd. Finally, Zacks Investment Research lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Cambrex Corporation presently has a consensus rating of “Hold” and a consensus target price of $65.67.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.